Ameritas Investment Partners Inc. Acquires New Position in Celldex Therapeutics, Inc. (NASDAQ:CLDX)

Ameritas Investment Partners Inc. acquired a new stake in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 3,074 shares of the biopharmaceutical company’s stock, valued at approximately $103,000.

Several other institutional investors and hedge funds have also recently made changes to their positions in the stock. RTW Investments LP lifted its stake in shares of Celldex Therapeutics by 14.2% during the first quarter. RTW Investments LP now owns 3,908,947 shares of the biopharmaceutical company’s stock valued at $80,524,000 after buying an additional 486,092 shares during the period. Redmile Group LLC raised its stake in Celldex Therapeutics by 24.9% during the first quarter. Redmile Group LLC now owns 3,387,788 shares of the biopharmaceutical company’s stock worth $69,788,000 after purchasing an additional 676,172 shares during the period. BlackRock Inc. raised its stake in Celldex Therapeutics by 12.4% during the first quarter. BlackRock Inc. now owns 967,873 shares of the biopharmaceutical company’s stock worth $19,938,000 after purchasing an additional 106,492 shares during the period. Millennium Management LLC raised its stake in Celldex Therapeutics by 145.3% during the first quarter. Millennium Management LLC now owns 505,163 shares of the biopharmaceutical company’s stock worth $10,406,000 after purchasing an additional 299,241 shares during the period. Finally, Geode Capital Management LLC raised its stake in Celldex Therapeutics by 17.9% during the first quarter. Geode Capital Management LLC now owns 352,697 shares of the biopharmaceutical company’s stock worth $7,265,000 after purchasing an additional 53,643 shares during the period. 75.77% of the stock is currently owned by institutional investors and hedge funds.

A number of equities analysts have weighed in on the stock. Zacks Investment Research raised shares of Celldex Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Tuesday, August 3rd. SVB Leerink assumed coverage on shares of Celldex Therapeutics in a research note on Friday, September 10th. They set an “outperform” rating and a $68.00 price target on the stock. HC Wainwright increased their price target on shares of Celldex Therapeutics from $54.00 to $60.00 and gave the stock a “buy” rating in a research note on Monday. Finally, Guggenheim assumed coverage on shares of Celldex Therapeutics in a research note on Thursday, July 22nd. They issued a “buy” rating and a $66.00 target price on the stock. One analyst has rated the stock with a hold rating and five have given a buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus target price of $50.40.

In related news, CFO Samuel Bates Martin sold 2,738 shares of the firm’s stock in a transaction on Tuesday, August 10th. The shares were sold at an average price of $45.25, for a total transaction of $123,894.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 1.90% of the stock is currently owned by company insiders.

Shares of CLDX stock opened at $53.30 on Wednesday. The company’s fifty day simple moving average is $46.28 and its 200-day simple moving average is $33.84. Celldex Therapeutics, Inc. has a 52 week low of $11.52 and a 52 week high of $56.17. The company has a market cap of $2.48 billion, a PE ratio of -31.92 and a beta of 3.06.

Celldex Therapeutics (NASDAQ:CLDX) last issued its earnings results on Thursday, August 5th. The biopharmaceutical company reported ($0.34) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.40) by $0.06. The business had revenue of $3.48 million for the quarter, compared to the consensus estimate of $1.13 million. Celldex Therapeutics had a negative net margin of 766.16% and a negative return on equity of 26.76%. As a group, equities analysts forecast that Celldex Therapeutics, Inc. will post -1.5 earnings per share for the current fiscal year.

Celldex Therapeutics Profile

Celldex Therapeutics, Inc engages in the business of development, manufacturing and commercialization of novel therapeutics for human health care. Its drug candidates have the ability to engage the human immune system and directly inhibit tumors to treat specific types of cancer and other diseases. Its pipeline includes Varlilumab, CDX-1140, and CDX-301, and CDX-3379.

Recommended Story: How is the S&P 500 index different from the DJIA?

Want to see what other hedge funds are holding CLDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celldex Therapeutics, Inc. (NASDAQ:CLDX).

Institutional Ownership by Quarter for Celldex Therapeutics (NASDAQ:CLDX)

Receive News & Ratings for Celldex Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celldex Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.